Drug
Pictilisib clinical trials
Also written GDC-0941.
- studies test it
- 13
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How studies write it
Studies that test it under each name
Name
Combined with it in one product
Studies by the year they started
13 studies that test it; most in 2013 (3)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 1 |
| 2015 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 10
- Phase 2
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 3
Genentech, Inc. (10) · Royal Marsden NHS Foundation Trust (1) · Vanderbilt-Ingram Cancer Center (1) · Medical Research Council (1)
Often tested with
Tested in the same studies.
Palbociclib (1) · Taselisib (1) · Bevacizumab (1) · Ketoconazole (1) · Erlotinib (1) · Apitolisib (1) · Cobimetinib (1)
Studies
Open first, then newest update. How each study uses pictilisib is read from its arms, and is right about nine times in ten.
Testing it · 13
- PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclibCompletedPhase 1Royal Marsden NHS Foundation TrustNCT02389842Written as Palbociclib + Taselisib / Pictilisib
- GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast CancerTerminatedPhase 1/2Vanderbilt-Ingram Cancer CenterNCT01918306Written as GDC -0941
- Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung CancerCompletedPhase 2Genentech, Inc.NCT01493843Written as pictilisib
- A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Participants With Locally Recurrent or Metastatic Breast CancerCompletedPhase 2Genentech, Inc.NCT01740336Written as GDC-0941
- A Study to Determine the Relative Bioavailability of a Tablet Formulation of GDC-0941 and the Effect of Ketoconazole on the Pharmacokinetics of the GDC-0941 TabletCompletedPhase 1Genentech, Inc.NCT01240226Written as GDC-0941
- Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid TumorsTerminatedPhase 1Genentech, Inc.NCT00996892Written as Pictilisib
- A Study of the Effect of Formulation and Tablet Hardness on the Bioavailability of Pictilisib in Healthy VolunteersCompletedPhase 1Genentech, Inc.NCT02092831Written as GDC-0941
- A Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid TumorsCompletedPhase 1Genentech, Inc.NCT00975182Written as GDC-0941
- Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor TherapyCompletedPhase 2Genentech, Inc.NCT01437566Written as GDC-0941
- A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or IntolerableCompletedPhase 1Genentech, Inc.NCT00876122Written as GDC-0941
- Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-0941 Following Single Oral Dose Administration in Healthy Male SubjectsCompletedPhase 1Genentech, Inc.NCT01474668Written as GDC-0941
- A Study of GDC-0941 in Participants With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or IntolerableCompletedPhase 1Genentech, Inc.NCT00876109Written as GDC-0941
- Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475Status unknownPhase 1/2Medical Research CouncilNCT02430363Written as Suppressor of the PI3K/Akt pathways
Given in every arm · 4 — pictilisib is usual care beside what is tested
- A Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0941 and the Effect of Food and Proton Pump Inhibition on GDC-0941 Tablet Pharmacokinetics in Healthy VolunteersCompletedPhase 1Genentech, Inc.NCT00999128Written as GDC-0941
- A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast CancerCompletedPhase 1Genentech, Inc.NCT00960960Written as Pictilisib
- Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based TherapyCompletedPhase 1Genentech, Inc.NCT00928330Written as GDC-0941
- A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung CancerCompletedPhase 1Genentech, Inc.NCT00974584Written as GDC-0941
Codes
What other systems call pictilisib · ClinicalTrials.gg INT005336
- UNII (FDA) ICY00EMP8PPICTILISIBConfirmed FDA, Wikidata
- Wikidata Q27088388pictilisibConfirmed FDA, Wikidata
- NCI Thesaurus C165479PictilisibOne source FDA
- DrugBank DB11663One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | ICY00EMP8P | PICTILISIB | Confirmed FDA, Wikidata |
| Wikidata | Q27088388 | pictilisib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C165479 | Pictilisib | One source FDA |
| DrugBank | DB11663 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.